论文部分内容阅读
根据最近一次在日本东京召开的国际实验液学会议上介绍:在对21名膀胱癌病人使用化学疗法的同时通过注射2～12次美国Amgen公司生产的嗜中性粒细胞集落刺激因子(简称G-CSF是一种中性糖蛋白)后,使病人体内的嗜中性白血球水平有了很大的提高。 Amgen公司的科学家指出,以上这些新发现是由美国Memorial Sloan-Kettering癌症中心在进行G-CSF的Ⅰ、Ⅱ期临床试验中得到的。其Ⅲ期的临床试验工作可望在本年度底开始。据Amgn公司报告,该产品的临床试验工
According to a recent meeting held in Tokyo, Japan, International Symposium on the use of chemotherapy in chemotherapy in 21 bladder cancer patients by injection of 2 to 12 times the United States Amgen’s production of neutrophil colony stimulating factor (referred to as G -CSF is a neutral glycoprotein), so that the patient’s neutrophil levels have been greatly improved. Amgen scientists point out that these new findings were obtained from phase I and phase II G-CSF clinical trials conducted by the Memorial Sloan-Kettering Cancer Center in the United States. Phase III clinical trial work is expected to begin at the end of the year. According to Amgn reports that the product’s clinical trial workers